E-ISSN 2250-0944
ISSN 2250-1150
doi: 10.31838/ijprt/16.02.4

Review Article

Inflammatory Biomarkers as Predictors of Renal Dysfunction in Obese Hypertensive Patients: A Comprehensive Review with Special Reference to the North Indian Population

Dr. Azeemul Hasan[1], Dr. Kaneez Abid[2], Dr. Akshay Kumar[3*]
[1]Junior Resident, Department of Biochemistry Maharaja Suhel Dev Autonomous State Medical College and Maharishi Balark Hospitals, Bahraich, Uttar Pradesh, India.
[2]Junior Resident (JR-I), MD Biochemistry, Department of Biochemistry Maharaja Suhel Dev Autonomous State Medical College and Maharishi Balark Hospitals, Bahraich, Uttar Pradesh, India.
[3*]Senior Resident, Department of Community Medicine Uttar Pradesh University of Medical Sciences (UPUMS), Saifai, Etawah, Uttar Pradesh, India.
Corresponding Author: Dr. Akshay Kumar
[3*]Senior Resident, Department of Community Medicine Uttar Pradesh University of Medical Sciences (UPUMS), Saifai, Etawah, Uttar Pradesh, India.
Email: [1]drazimulhasan786@gmail.com, [2]drkaneezabid@gmail.com, [3]akshayksaini339@gmail.com
Received: 17.09.2026, Revised: 11.10.2026, Accepted: 05.11.2026

ABSTRACT
Chronic kidney disease (CKD) has emerged as a major global public health concern due to its increasing prevalence and strong association with cardiovascular morbidity and mortality. The burden of CKD is particularly amplified in individuals with obesity and hypertension, where complex metabolic and inflammatory mechanisms contribute to progressive renal damage. Bojan Stopic (2022) described CKD as a significant contributor to overall morbidity and emphasized its independent role in increasing cardiovascular risk, highlighting the need for early identification of predictive markers [1].
In recent years, inflammation has been recognized as a key pathophysiological link connecting obesity, hypertension, and renal dysfunction. Traditional diagnostic tools such as serum creatinine and estimated glomerular filtration rate (eGFR) are limited in detecting early renal injury, thereby necessitating the identification of more sensitive biomarkers. Inflammatory markers such as C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), interleukins, tumor necrosis factor-alpha (TNF-α), and emerging biomarkers like kidney injury molecule-1 (KIM-1), monocyte chemoattractant protein-1 (MCP-1), and YKL-40 have demonstrated potential in early prediction and monitoring of renal dysfunction.
This review aims to comprehensively analyze the role of inflammatory biomarkers as predictors of renal dysfunction in obese hypertensive patients, with a special emphasis on the North Indian population where epidemiological transitions are rapidly increasing disease burden. Understanding these biomarkers may facilitate early diagnosis, risk stratification, and improved therapeutic interventions.

INTRODUCTION

Chronic kidney disease represents a progressive decline in renal function that ultimately leads to end-stage renal disease if not identified and managed at an early stage. The increasing prevalence of CKD worldwide is closely linked to the rising incidence of obesity, hypertension, and metabolic syndrome. K.R.D. Pinto (2021) highlighted that CKD is among the most prevalent chronic diseases globally and is associated with substantial morbidity, thereby emphasizing the importance of identifying modifiable risk factors [2].
Obesity has reached epidemic proportions globally and is now recognized as a major contributor to renal pathology. The excessive accumulation of adipose tissue is not merely a storage of fat but functions as an active endocrine organ producing inflammatory cytokines and adipokines that adversely affect multiple organ systems, including the kidneys. Isha Sharma (2021) explained that the incidence of obesity-related renal disorders has increased dramatically over recent years, reflecting the expanding burden of metabolic diseases [3].
Hypertension further exacerbates renal damage and frequently coexists with obesity, creating a synergistic effect that accelerates kidney injury. John E. Hall (2020) demonstrated that obesity contributes to a large proportion of essential hypertension cases and plays a critical role in the development of cardiovascular and renal diseases [4]. The coexistence of these conditions leads to increased intraglomerular pressure,

endothelial dysfunction, and progressive nephron loss.

An important underlying mechanism linking obesity, hypertension, and renal dysfunction is chronic low-grade inflammation. Unlike acute inflammation, which is protective, chronic inflammation leads to persistent tissue injury and fibrosis. Traditional diagnostic markers often fail to detect early renal involvement, making inflammatory biomarkers an important area of research.

In the Indian context, particularly in North India, rapid urbanization, dietary changes, and sedentary lifestyle patterns have significantly increased the prevalence of obesity and hypertension. However, there is limited data evaluating the role of inflammatory biomarkers in predicting renal dysfunction in this population, indicating a critical research gap.

Pathophysiological Link Between Obesity, Hypertension and Renal Dysfunction

The relationship between obesity, hypertension, and renal dysfunction is complex and involves multiple interrelated mechanisms including hemodynamic alterations, metabolic disturbances, neurohormonal activation, and inflammatory pathways.

From a hemodynamic perspective, obesity leads to significant changes in renal blood flow and glomerular dynamics. Increased body mass results in elevated renal plasma flow and glomerular filtration rate, a condition known as hyperfiltration. Isha Sharma (2021**)** described that obesity induces increased glomerular filtration, leading to enlargement of the glomerulus, which initially serves as a compensatory mechanism but eventually contributes to structural damage and decline in renal function [3].

Similarly, Kalapala Vanaja (2024) reported that obesity is associated with hyperfiltration, increased albuminuria, and early renal structural changes, all of which are indicators of impending renal dysfunction [5]. Persistent hyperfiltration results in glomerular hypertrophy, basement membrane thickening, and mesangial expansion, ultimately leading to glomerulosclerosis.

Neurohormonal mechanisms further contribute to this process. John E. Hall (2020) explained that obesity leads to increased renal sodium reabsorption, activation of the renin–angiotensin–aldosterone system, and compression of renal structures by surrounding adipose tissue, all of which contribute to sustained hypertension and progressive renal injury [4]. These mechanisms also promote volume expansion and increase intraglomerular pressure.

Metabolic syndrome plays a crucial role in linking obesity to renal dysfunction. Florian G. Scurt (2023) described metabolic syndrome as a proinflammatory and oxidative stress state that leads to endothelial dysfunction and microvascular damage. The kidney, being highly vascular, is particularly susceptible to these changes, resulting in accelerated progression of chronic kidney disease [6].




Fig 1 - Mechanisms and Factors Linking Malnutrition and Resulting Uric Acid Production and Gut Dysbiosis with Chronic Liver and Kidney Injury [6]

Inflammation acts as a central mediator connecting these processes. Adipose tissue releases pro-inflammatory cytokines such as TNF-α and interleukins, which contribute to endothelial dysfunction, oxidative stress, and activation of fibrotic pathways. These mechanisms collectively lead to progressive renal damage.

Role of Inflammation in Renal Injury

Inflammation plays a pivotal role in the initiation and progression of renal injury. While acute inflammation is a protective response, chronic inflammation leads to persistent tissue damage and fibrosis, which are hallmarks of chronic kidney disease.

Jeremy Puthumana (2021) emphasized that inflammation is the principal response to kidney injury and that prolonged inflammatory activity leads to renal fibrosis, which is a key determinant of disease progression [7]. Fibrosis results from the activation of fibroblasts and deposition of extracellular matrix components, leading to irreversible structural damage.

Clinical studies have consistently demonstrated elevated levels of inflammatory markers in patients with CKD. Anamika Das (2022) showed that inflammatory markers such as C-reactive protein, erythrocyte sedimentation rate, and neutrophil-to-lymphocyte ratio are significantly elevated in CKD patients compared to healthy controls, indicating a systemic inflammatory state [8].

Furthermore, endothelial dysfunction plays a significant role in mediating inflammation-related damage. Anamika Das (2022) also highlighted that non-traditional risk factors such as oxidative stress and endothelial dysfunction contribute significantly to cardiovascular and renal complications in CKD patients [8].

Chronic inflammation leads to activation of multiple cellular pathways, recruitment of immune cells, and release of cytokines, all of which contribute to progressive renal damage. This underscores the importance of identifying inflammatory biomarkers for early detection and intervention.

Molecular Mechanisms of Inflammation in Renal Disease

At the molecular level, inflammatory signaling pathways play a crucial role in the pathogenesis of renal disease. Among these pathways, the nuclear factor kappa B (NF-κB) pathway is one of the most extensively studied.

Haisong Zhang (2015) described NF-κB as a key transcription factor involved in regulating genes responsible for inflammation, immune responses, and cell survival. Activation of NF-κB leads to the expression of pro-inflammatory cytokines, chemokines, and adhesion molecules, thereby amplifying the inflammatory response within renal tissues [9].




FIG.2 - Canonical and Noncanonical NF-Kb Signaling Pathways [9]

Persistent activation of NF-κB signaling contributes to chronic inflammation, cellular injury, and fibrosis. This pathway is activated by various stimuli including oxidative stress, cytokines, and metabolic disturbances, all of which are commonly present in obese hypertensive individuals.

In addition to NF-κB, oxidative stress plays a significant role in renal inflammation. Increased production of reactive oxygen species leads to cellular damage, lipid peroxidation, and activation of inflammatory pathways. This further exacerbates renal injury and accelerates disease progression.

Epidemiological Evidence Linking Obesity to Ckd

Epidemiological studies provide strong evidence supporting the association between obesity and chronic kidney disease.

K.R.D. Pinto (2021) reported that obese individuals have a significantly higher risk of developing CKD compared to non-obese individuals, with a relative risk of approximately 1.81, indicating a strong association between obesity and renal dysfunction [2].

Similarly, Saurabh Kothari (2023) demonstrated that the prevalence of renal insufficiency is higher in obese hypertensive patients compared to non-obese hypertensive individuals, highlighting the additive effect of obesity on renal disease progression [10].

Obesity contributes to renal dysfunction through multiple mechanisms including inflammation, metabolic disturbances, and hemodynamic changes. These findings emphasize the importance of early identification and management of obesity to prevent the progression of chronic kidney disease.

Classification of Inflammatory Biomarkers in Renal Dysfunction

Inflammatory biomarkers involved in renal dysfunction among obese hypertensive patients can be broadly classified into traditional markers, cytokine-based markers, and emerging or novel biomarkers. These biomarkers reflect different stages of inflammation, tissue injury, and repair, thereby providing a comprehensive understanding of disease progression.

Traditional biomarkers are widely available and routinely used in clinical practice. These include C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and neutrophil–lymphocyte ratio (NLR), which serve as indirect indicators of systemic inflammation. Cytokine-based biomarkers such as interleukins and tumor necrosis factor-alpha represent more specific mediators of inflammatory pathways. Emerging biomarkers, including kidney injury molecule-1 (KIM-1), monocyte chemoattractant protein-1 (MCP-1), and YKL-40, provide insights into early renal injury and repair mechanisms.

Bojan Stopic (2022) emphasized that multiple categories of biomarkers, including inflammatory markers, oxidative stress markers, and kidney injury markers, are important predictors of adverse outcomes in chronic kidney disease, highlighting the need for a multidimensional biomarker approach [1].

Traditional Inflammatory Biomarkers

C-Reactive Protein (Crp)

C-reactive protein is one of the most extensively studied inflammatory biomarkers and is widely used in clinical settings due to its availability and cost-effectiveness. It is an acute-phase reactant synthesized by the liver in response to inflammatory stimuli, particularly interleukin-6.

Anamika Das (2022) demonstrated that CRP levels are significantly elevated in patients with chronic kidney disease compared to healthy individuals, reflecting a persistent inflammatory state [8]. Elevated CRP levels are associated with endothelial dysfunction, increased vascular permeability, and progression of renal injury.

In obese hypertensive patients, CRP levels are often elevated due to the pro-inflammatory nature of adipose tissue. Adipocytes release cytokines that stimulate CRP production, thereby linking obesity to systemic inflammation and renal dysfunction.

Erythrocyte Sedimentation Rate (Esr)

ESR is another nonspecific marker of inflammation that reflects the presence of acute and chronic inflammatory processes. Although it lacks specificity, it remains a useful indicator of systemic inflammation in clinical practice.

Anamika Das (2022) reported that ESR levels are significantly higher in CKD patients, supporting the presence of chronic inflammation [8]. Elevated ESR values indicate increased fibrinogen levels and altered plasma protein composition, both of which are associated with inflammatory states.

Neutrophil–Lymphocyte Ratio (Nlr)

The neutrophil–lymphocyte ratio is an emerging biomarker that reflects the balance between innate and adaptive immune responses. It is inexpensive, easily accessible, and has gained increasing attention as a prognostic marker.

Anamika Das (2022) highlighted that NLR is being increasingly validated as a prognostic marker for endothelial dysfunction and

cardiovascular risk in CKD patients [8]. Elevated NLR indicates systemic inflammation and has been associated with poor clinical outcomes.

Cytokine-Based Inflammatory Biomarkers
Interleukins

Interleukins are a group of cytokines that play a crucial role in mediating immune and inflammatory responses. Among these, interleukin-6 (IL-6) and interleukin-18 (IL-18) are particularly important in the context of renal dysfunction.

Bojan Stopic (2022) identified interleukin-18 as a significant inflammatory biomarker associated with adverse outcomes in chronic kidney disease [1]. Interleukins contribute to endothelial dysfunction, vascular inflammation, and progression of renal injury.

Tumor Necrosis Factor-Alpha (Tnf-A)

Tumor necrosis factor-alpha is a pro-inflammatory cytokine that plays a central role in inflammation and immune regulation. It contributes to renal injury by promoting apoptosis, oxidative stress, and fibrosis.

In obese individuals, adipose tissue acts as a source of TNF-α, thereby linking obesity to chronic inflammation and renal dysfunction. Elevated TNF-α levels are associated with glomerular injury and progression of CKD.

Emerging and Novel Biomarkers
Kidney Injury Molecule-1 (Kim-1)

KIM-1 is a sensitive marker of tubular injury and is elevated in early stages of kidney damage. It provides an advantage over traditional markers by detecting subclinical injury.

Bojan Stopic (2022) included KIM-1 as a biomarker of acute kidney injury and emphasized its role in predicting adverse outcomes in CKD patients [1].

Monocyte Chemoattractant Protein-1 (Mcp-1)

MCP-1 is a chemokine involved in the recruitment of monocytes to sites of inflammation. It plays a critical role in the development of renal inflammation and fibrosis.

Jeremy Puthumana (2021) demonstrated that higher levels of MCP-1 are associated with greater decline in eGFR and increased risk of progression to chronic kidney disease [7].

Ykl-40

YKL-40 is a marker of inflammation and tissue remodeling. It is produced by macrophages and neutrophils and is associated with fibrosis and disease progression.

Jeremy Puthumana (2021) showed that elevated YKL-40 levels are associated with increased incidence of renal outcomes, indicating its role as a predictive biomarker [7].

Nuclear Factor–Kappa B (Nf-Kb)

Nuclear factor-kappa B (NF-κB) is a central regulator of inflammatory signaling pathways and plays a crucial role in the pathogenesis of renal diseases. It is a transcription factor that controls the expression of multiple genes involved in immune responses, inflammation, cell proliferation, and survival.

Haisong Zhang (2015) explained that NF-κB is a ubiquitously expressed transcription factor that remains inactive in the cytoplasm under normal conditions and becomes activated in response to immune and stress stimuli, after which it translocates to the nucleus to regulate gene expression [9]. This activation occurs through canonical and non-canonical signaling pathways and results in the production of pro-inflammatory cytokines, chemokines, and adhesion molecules.

In obese hypertensive patients, NF-κB activation is triggered by multiple factors including oxidative stress, adipokines, and metabolic disturbances. Persistent activation of this pathway leads to chronic inflammation, endothelial dysfunction, and progressive renal injury. NF-κB also plays a key role in promoting fibrosis by inducing the expression of fibrogenic cytokines and growth factors.

The dysregulation of NF-κB signaling has been implicated in various renal pathologies including diabetic nephropathy, hypertensive nephrosclerosis, and glomerulonephritis. Targeting NF-κB signaling pathways may therefore represent a potential therapeutic strategy for preventing inflammation-mediated renal damage.

Role of Biomarkers in Early Detection and Progression

Inflammatory biomarkers play a critical role in the early detection and monitoring of renal dysfunction. Unlike traditional markers, which reflect advanced stages of disease, these biomarkers provide insights into early pathological changes.

Jeremy Puthumana (2021) emphasized that biomarker levels measured after kidney injury can identify patients at risk for disease progression, thereby improving clinical decision-making and patient outcomes [7].

The use of multiple biomarkers in combination enhances predictive accuracy. A multimarker

approach allows for better risk stratification and early intervention, particularly in high-risk populations such as obese hypertensive individuals.

Obesity–Inflammation–Renal Axis

The interplay between obesity, inflammation, and renal dysfunction represents a complex and self-perpetuating pathogenic axis that significantly contributes to the development and progression of chronic kidney disease. Obesity is no longer considered merely a state of excess fat accumulation but rather a chronic low-grade inflammatory condition characterized by persistent activation of immune and metabolic pathways.

Adipose tissue functions as an active endocrine organ that secretes a wide range of bioactive substances, including adipokines, cytokines, and chemokines. These mediators play a crucial role in initiating and sustaining systemic inflammation. Florian G. Scurt (2023) described metabolic syndrome as a condition marked by a proinflammatory state and increased oxidative stress, both of which contribute to endothelial dysfunction and renal injury [6]. This chronic inflammatory environment leads to structural and functional alterations in the kidney.

Obesity-induced inflammation is primarily mediated through adipocyte hypertrophy and infiltration of immune cells such as macrophages. These immune cells release pro-inflammatory cytokines including TNF-α, interleukins, and MCP-1, which amplify the inflammatory response. This cascade ultimately results in glomerular injury, tubular damage, and interstitial fibrosis.

Role of Adipokines in Renal Dysfunction

Adipokines are bioactive molecules secreted by adipose tissue that regulate metabolic and inflammatory processes. In obesity, there is an imbalance between pro-inflammatory and anti-inflammatory adipokines, leading to a state of chronic inflammation.

Pro-inflammatory adipokines such as leptin, resistin, and TNF-α are elevated in obese individuals and contribute to renal injury. These molecules promote oxidative stress, endothelial dysfunction, and activation of fibrotic pathways. On the other hand, adiponectin, an anti-inflammatory adipokine, is reduced in obesity, further exacerbating the inflammatory state.

John E. Hall (2020) highlighted that adipocyte-derived cytokines such as leptin play a significant role in increasing sympathetic nervous system activity and contributing to hypertension, thereby linking obesity to renal dysfunction [4]. Elevated leptin levels also promote sodium retention and increase blood pressure, further aggravating renal damage.

The imbalance of adipokines contributes to the progression of kidney disease by enhancing inflammation, promoting fibrosis, and impairing normal renal function.

Immunological Mechanisms in Renal Injury

The immune system plays a critical role in mediating inflammation in obese hypertensive individuals. Both innate and adaptive immune responses are involved in the pathogenesis of renal dysfunction.

Activation of immune cells leads to the release of inflammatory mediators that cause tissue injury. John E. Hall (2020) explained that activation of immune cells results in the production of cytokines and chemokines that contribute to vascular and target organ injury, including the kidneys [4].

Macrophages infiltrate adipose tissue and renal tissues, releasing pro-inflammatory cytokines that exacerbate inflammation. T lymphocytes also play a role by promoting immune-mediated injury and fibrosis. This immune activation contributes to endothelial dysfunction, increased vascular permeability, and progression of renal damage.

Endothelial Dysfunction and Oxidative Stress

Endothelial dysfunction is a key event in the progression of renal disease and is closely associated with inflammation and oxidative stress. The endothelium plays a vital role in maintaining vascular homeostasis, and its dysfunction leads to impaired vasodilation, increased vascular permeability, and pro-inflammatory states.

Anamika Das (2022) emphasized that endothelial dysfunction is a major non-traditional risk factor contributing to cardiovascular and renal complications in CKD patients [8]. The inability of the endothelium to regulate vascular tone and maintain barrier function leads to increased susceptibility to injury.

Oxidative stress further aggravates endothelial dysfunction by generating reactive oxygen species that damage cellular structures and activate inflammatory pathways. This results in a vicious cycle where inflammation and oxidative stress perpetuate each other, leading to progressive renal injury.

Renal Hemodynamic Alterations in Obesity and Hypertension

Renal hemodynamic changes are central to the development of kidney dysfunction in obese hypertensive patients. These changes include increased renal blood flow, hyperfiltration, and altered pressure dynamics within the glomerulus.

Isha Sharma (2021) described that obesity leads to increased glomerular filtration rate and enlargement of the glomerulus, which initially compensates for increased metabolic demand but eventually leads to renal damage [3]. Hyperfiltration increases mechanical stress on the glomerular capillaries, resulting in structural damage.

Additionally, obesity leads to increased renal tubular sodium reabsorption, which contributes to hypertension. Saurabh Kothari (2023) explained that increased sodium reabsorption and activation of neurohormonal systems result in volume expansion and elevated blood pressure, further exacerbating renal injury [10].

Persistent hemodynamic stress leads to progressive decline in renal function, highlighting the importance of early intervention.

Interaction Between Metabolic Syndrome and Ckd

Metabolic syndrome is a cluster of conditions including obesity, hypertension, insulin resistance, and dyslipidemia that collectively increase the risk of cardiovascular and renal diseases.

Florian G. Scurt (2023) described metabolic syndrome as a major contributor to the development and progression of chronic kidney disease, emphasizing its role in causing microvascular damage and endothelial dysfunction [6].

The presence of metabolic syndrome accelerates renal injury through multiple mechanisms, including inflammation, oxidative stress, and altered hemodynamics. These factors interact synergistically, leading to rapid progression of CKD.

Clinical Correlation in Obese Hypertensive Patients

Clinical studies have consistently demonstrated that obese hypertensive patients are at a higher risk of developing renal dysfunction compared to non-obese individuals.

Kalapala Vanaja (2024) reported significant differences in renal parameters among obese and hypertensive patients, including higher serum creatinine, urea levels, and reduced eGFR, indicating impaired renal function [5].

Similarly, Saurabh Kothari (2023) found that the prevalence of renal insufficiency is higher in obese hypertensive patients compared to non-obese hypertensive individuals, further supporting the role of obesity as an aggravating factor in renal disease [10].

These findings highlight the importance of early identification and management of obesity and hypertension to prevent renal complications.

Special Reference to North Indian Population

The North Indian population is experiencing a rapid increase in the prevalence of obesity and hypertension due to lifestyle transitions, urbanization, and dietary changes. This has led to a corresponding rise in chronic kidney disease.

Kalapala Vanaja (2024) highlighted that obesity prevalence in India is increasing due to changes in lifestyle and socioeconomic factors, making it a significant public health concern [5].

In addition, limited awareness, delayed diagnosis, and lack of access to healthcare services contribute to the progression of renal disease in this population. There is also a lack of large-scale studies evaluating inflammatory biomarkers in North Indian populations, indicating a need for focused research.

Understanding population-specific risk factors and biomarker profiles is essential for developing targeted screening and intervention strategies.

Diagnostic and Predictive Value of Inflammatory Biomarkers

Inflammatory biomarkers have gained considerable importance in recent years as tools for early diagnosis, risk stratification, and monitoring of renal dysfunction, particularly in high-risk populations such as obese hypertensive patients. Unlike traditional markers, which often indicate established renal damage, inflammatory biomarkers reflect early pathophysiological changes occurring at the molecular and cellular levels.

Early detection of renal dysfunction is crucial for preventing disease progression and improving clinical outcomes. Conventional diagnostic parameters such as serum creatinine and estimated glomerular filtration rate (eGFR) are limited by their inability to detect early renal injury, as significant nephron loss must occur before changes become evident. In contrast, inflammatory biomarkers provide insight into ongoing pathological processes such as inflammation, oxidative stress, and endothelial dysfunction.

Jeremy Puthumana (2021) demonstrated that specific biomarkers measured after kidney injury can identify patients at risk for long-term progression to chronic kidney disease, thereby

aiding in early intervention and improving prognostic accuracy [7]. This highlights the importance of incorporating biomarker-based approaches into routine clinical practice.

Sensitivity and Specificity of Biomarkers

The clinical utility of any biomarker depends on its sensitivity and specificity in detecting disease. Inflammatory biomarkers vary in their diagnostic accuracy, with some being more sensitive for early detection while others are more specific for advanced disease.

Traditional markers such as CRP and ESR are highly sensitive indicators of systemic inflammation but lack specificity for renal disease. Elevated levels may be observed in a variety of inflammatory conditions, limiting their diagnostic precision. However, their widespread availability and cost-effectiveness make them valuable screening tools.

Anamika Das (2022) demonstrated that CRP and ESR levels are significantly elevated in CKD patients, supporting their role as indicators of systemic inflammation, although they cannot independently confirm renal pathology [8].

In contrast, emerging biomarkers such as KIM-1, MCP-1, and YKL-40 offer greater specificity for renal injury. These markers are directly involved in kidney injury and repair mechanisms, making them more reliable indicators of renal dysfunction.

Bojan Stopic (2022) emphasized that combining multiple biomarkers improves diagnostic accuracy and provides a more comprehensive assessment of disease progression [1].

Comparison Between Traditional and Novel Biomarkers

A comparison between traditional and novel biomarkers highlights the advantages and limitations of each category. Traditional biomarkers are easily accessible, cost-effective, and widely used in clinical practice. However, they primarily reflect systemic inflammation and are not specific to renal injury.

Novel biomarkers, on the other hand, provide a more direct assessment of kidney damage. For instance, KIM-1 is a marker of tubular injury, while MCP-1 reflects inflammatory cell recruitment, and YKL-40 indicates tissue remodeling and fibrosis.

Jeremy Puthumana (2021) demonstrated that higher levels of MCP-1 and YKL-40 are associated with greater decline in eGFR and increased risk of renal outcomes, indicating their superior predictive value compared to traditional markers [7].

However, the use of novel biomarkers is limited by factors such as high cost, lack of standardization, and limited availability, particularly in resource-constrained settings.

Multi-Biomarker Approach

The use of a single biomarker may not adequately capture the complexity of renal disease. Therefore, a multi-biomarker approach has been proposed to improve diagnostic and prognostic accuracy.

Jeremy Puthumana (2021) highlighted that combining multiple biomarkers into a composite score improves risk prediction and provides better prognostic information compared to individual markers alone [7].

This approach allows for the assessment of multiple aspects of disease, including inflammation, injury, and repair. For example, combining CRP (inflammation), KIM-1 (tubular injury), and MCP-1 (immune activation) provides a comprehensive understanding of disease progression.

Role in Risk Stratification

Inflammatory biomarkers play a crucial role in identifying high-risk individuals who are more likely to develop renal dysfunction. This is particularly important in obese hypertensive patients, where early intervention can prevent disease progression.

K.R.D. Pinto (2021) demonstrated that obesity significantly increases the risk of developing chronic kidney disease, emphasizing the need for early identification of high-risk individuals [2].

Biomarkers can be used to stratify patients into different risk categories, allowing for personalized treatment strategies. High-risk individuals can be targeted for intensive interventions such as lifestyle modification, pharmacological therapy, and regular monitoring.

Role in Monitoring Disease Progression

In addition to early detection, inflammatory biomarkers are useful in monitoring disease progression and response to treatment. Changes in biomarker levels over time can provide valuable information regarding disease activity and therapeutic efficacy.

Jeremy Puthumana (2021) demonstrated that biomarker levels correlate with changes in eGFR and can predict long-term renal outcomes, making them valuable tools for monitoring disease progression [7].

Regular monitoring of biomarkers allows clinicians to assess the effectiveness of

interventions and make necessary adjustments to treatment plans.

Limitations and Challenges

Despite their potential, the use of inflammatory biomarkers in clinical practice is associated with several limitations and challenges. One of the major limitations is the lack of standardization in measurement techniques and reference values. Variability in laboratory methods can affect the accuracy and reproducibility of results.

Another challenge is the cost and availability of novel biomarkers, which may limit their use in developing countries such as India. Traditional biomarkers, although less specific, remain more accessible and practical in such settings.

Additionally, inflammatory biomarkers may be influenced by factors other than renal disease, such as infections, autoimmune conditions, and malignancies, which can confound their interpretation.

Bojan Stopic (2022) emphasized that determining appropriate reference values for biomarkers is challenging, as their levels are influenced by renal function and other clinical variables [1].

Clinical Implications

The integration of inflammatory biomarkers into clinical practice has the potential to transform the management of renal disease. Early detection, accurate risk stratification, and effective monitoring can significantly improve patient outcomes.

In obese hypertensive patients, the use of biomarkers can facilitate timely interventions, prevent disease progression, and reduce the burden of chronic kidney disease.

However, further research is required to validate these biomarkers, establish standardized protocols, and assess their cost-effectiveness in different populations.

DISCUSSION

The present review highlights the critical role of inflammatory biomarkers in predicting renal dysfunction among obese hypertensive patients. The interaction between obesity, hypertension, and inflammation forms a complex pathophysiological network that accelerates renal injury and progression to chronic kidney disease. The integration of molecular, clinical, and epidemiological evidence clearly demonstrates that inflammation is not merely a secondary phenomenon but a primary driver of renal damage.

Obesity contributes to renal dysfunction through multiple mechanisms including hemodynamic changes, metabolic disturbances, and chronic low-grade inflammation. The expansion of adipose tissue leads to increased secretion of pro-inflammatory cytokines and adipokines, which in turn promote endothelial dysfunction and fibrosis. John E. Hall (2020) emphasized that inflammatory mediators derived from adipose tissue play a significant role in vascular and renal injury, thereby linking obesity directly to kidney dysfunction [4].

Hypertension further exacerbates this process by increasing intraglomerular pressure and promoting structural damage to the renal vasculature. The coexistence of obesity and hypertension results in a synergistic effect that accelerates disease progression. Saurabh Kothari (2023) demonstrated that obese hypertensive patients have a higher prevalence of renal insufficiency compared to non-obese individuals, highlighting the additive impact of these conditions [10].

Inflammatory biomarkers provide valuable insights into these underlying mechanisms. Traditional markers such as CRP, ESR, and NLR reflect systemic inflammation, while novel biomarkers such as KIM-1, MCP-1, and YKL-40 provide more specific information regarding renal injury and repair processes. Jeremy Puthumana (2021) showed that elevated levels of MCP-1 and YKL-40 are associated with greater decline in renal function and increased risk of adverse outcomes, underscoring their prognostic significance [7].

The role of molecular pathways, particularly NF-κB signaling, further reinforces the importance of inflammation in renal disease. Haisong Zhang (2015) highlighted that NF-κB regulates the expression of genes involved in inflammation and immune responses, and its persistent activation contributes to chronic renal injury and fibrosis [9]. Targeting such pathways may offer new therapeutic opportunities.

In the Indian context, particularly in North India, the burden of obesity and hypertension is rapidly increasing. Lifestyle changes, urbanization, and dietary patterns have significantly contributed to this trend. However, there is a lack of large-scale studies evaluating inflammatory biomarkers in this population, indicating a significant research gap.

Future Directions

Future research should focus on identifying and validating novel inflammatory biomarkers that can detect renal dysfunction at an early stage.

There is a need for longitudinal studies to establish causal relationships between biomarkers and disease progression.

The development of multi-biomarker panels integrating traditional and novel markers may improve diagnostic accuracy and predictive value. Bojan Stopic (2022) emphasized the importance of combining different categories of biomarkers to enhance risk prediction and clinical outcomes [1].

Advancements in molecular biology and genomics may also lead to the identification of new targets for therapeutic intervention. Understanding the role of signaling pathways such as NF-κB and their interaction with metabolic and inflammatory processes may open new avenues for treatment.

In addition, there is a need to develop cost-effective and accessible diagnostic tools that can be implemented in resource-limited settings. This is particularly important in countries like India, where healthcare resources may be limited.

Research Gaps (with Special Reference to North India)

Despite the growing body of evidence, several research gaps remain, particularly in the context of the North Indian population. Most studies on inflammatory biomarkers and renal dysfunction have been conducted in Western populations, and their findings may not be directly applicable to Indian populations due to differences in genetics, lifestyle, and environmental factors.

There is a lack of large-scale epidemiological studies evaluating the prevalence and predictive value of inflammatory biomarkers in North India. Additionally, there is limited data on the interaction between socioeconomic factors, dietary habits, and biomarker profiles.

Kalapala Vanaja (2024) highlighted the increasing prevalence of obesity in India due to lifestyle and socioeconomic changes, indicating the need for region-specific research [5].

Furthermore, standard reference values for biomarkers in the Indian population have not been well established, which may affect their clinical applicability. Addressing these gaps is essential for developing targeted screening and intervention strategies.

Recommendations

Based on the findings of this review, several recommendations can be proposed for clinical practice and future research:

1. Early screening of obese hypertensive patients using inflammatory biomarkers should be encouraged to detect renal dysfunction at an early stage.
2. A multi-biomarker approach should be adopted to improve diagnostic accuracy and risk stratification.
3. Lifestyle interventions including weight reduction, dietary modification, and physical activity should be promoted to reduce inflammation and prevent renal damage.
4. Further research should focus on validating novel biomarkers and developing cost-effective diagnostic tools.
5. Large-scale studies should be conducted in the North Indian population to establish region-specific data and guidelines.

CONCLUSION

Inflammatory biomarkers play a crucial role in the early detection and prediction of renal dysfunction in obese hypertensive patients. The evidence clearly demonstrates that inflammation is a central mechanism linking obesity and hypertension to kidney disease.

Traditional biomarkers such as CRP and ESR provide valuable information regarding systemic inflammation, while novel biomarkers such as KIM-1, MCP-1, and YKL-40 offer greater specificity for renal injury. The integration of these biomarkers into clinical practice has the potential to improve early diagnosis, risk stratification, and monitoring of disease progression.

K.R.D. Pinto (2021) confirmed that obesity significantly increases the risk of chronic kidney disease, emphasizing the importance of early identification and intervention [2]. Similarly, Jeremy Puthumana (2021) highlighted the role of biomarkers in predicting disease progression and improving clinical outcomes [7].

In the North Indian context, the rising prevalence of obesity and hypertension underscores the need for increased awareness, early screening, and targeted interventions. Addressing existing research gaps and implementing biomarker-based approaches can significantly reduce the burden of chronic kidney disease.

REFERENCES

1. Stopić B, Medić-Brkić B, Savić-Vujović K, Davidović Ž, Todorović J, Dimković N. Biomarkers and predictors of adverse cardiovascular events in different stages of chronic kidney disease. *Dose Response*. 2022;20(3):15593258221127568. doi:10.1177/15593258221127568.

2. Pinto KRD, Feckinghaus CM, Hirakata VN. Obesity as a predictive factor for chronic kidney disease in adults: systematic review and meta-analysis. *Braz J Med Biol Res*. 2021;54(4):e10022. doi:10.1590/1414-431X202010022.
3. Sharma I, Liao Y, Zheng X, Kanwar YS. New pandemic: obesity and associated nephropathy. *Front Med (Lausanne)*. 2021;8:673556. doi:10.3389/fmed.2021.673556.
4. Hall JE, Mouton AJ, da Silva AA, Omoto ACM, Wang Z, Li X, do Carmo JM. Obesity, kidney dysfunction, and inflammation: interactions in hypertension. *Cardiovasc Res*. 2021;117(8):1859–1876. doi:10.1093/cvr/cvaa336.
5. Vanaja K, Lavanya YR, Madhavi Latha J. A clinical comparative study of renal parameters of obese and hypertensive patients with non-obese hypertensive patients. *Int J Curr Pharm Res*. 2025;17(1):6057. doi:10.22159/ijcpr.2025v17i1.6057.
6. Scurt FG, Ganz MJ, Herzog C, Bose K, Mertens PR, Chatzikyrkou C. Association of metabolic syndrome and chronic kidney disease. *Obes Rev*. 2024;25:e13649. doi:10.1111/obr.13649.
7. Puthumana J, Thiessen-Philbrook H, Xu L, Coca SG, Garg AX, Himmelfarb J, et al. Biomarkers of inflammation and repair in kidney disease progression. *J Clin Invest*. 2021;131(3):e139927. doi:10.1172/JCI139927.
8. Das A, Barman B, Bhattacharya P, Lynrah KG, Tiewsoh I, Phukan P. Inflammation and its determinants in patients with chronic kidney disease: a study from North Eastern region of India. *Cureus*. 2022;14(1):e20917. doi:10.7759/cureus.20917.
9. Zhang H, Sun SC. NF-κB in inflammation and renal diseases. *Cell Biosci*. 2015;5:63. doi:10.1186/s13578-015-0056-4.
10. Kothari S, Shetty V, Bhori M. Clinical profile and comparison of renal insufficiency in obese and non-obese hypertensive patients: a cross-sectional comparative study. *Panacea J Med Sci*. 2023;13(3):704–711. doi:10.18231/j.pjms.2023.129.